source
- Kairos pushes prostate cancer drug ENV-105 into earlier treatment line after promising mid-phase dataKairos Pharma announced a change to its phase 2 trial of ENV-105, a prostate cancer candidate, moving it to an earlier line of therapy. The modified protocol will enroll patients whose PSA rises a…
- Abbott receives FDA clearance for CardioMEMS HF System updates enabling home pressure monitoring via smartphone appAbbott announced that the U.S. Food and Drug Administration has cleared updated software for its CardioMEMS HF System. The changes add a patient facing component through the CardioGuide HF mobile a…Fierce Biotech · 15d agoApprovalPositive